USPTO issues patent to Oragenics' In Vivo Induced Antigen Technology

Florida-based nutraceutical company, Oragenics, Inc. (OTCBB: ORNI) (, announced today the issuance of patent number 8,034,571 from the United States Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT).

This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies. We believe that IVIAT is faster, more cost-efficient and significantly more sensitive than competing technologies such as differential proteomics and microarrays. In addition, our technology uses the actual diseased host rather than an animal model, so that biomarkers that we discover are more likely to be of high clinical value.

"IVIAT, and sister technology CMAT (Change Mediated Antigen Technology), add tremendous value to our biomarker discovery portfolio," stated Dr. Martin Handfield, Director of Research and Development for Oragenics. "These two technologies could lead to the discovery of new proteins that could be extremely useful in the design of novel diagnostic tests, vaccine targets and antibiotherapy strategies," Dr. Handfield added.

"Oragenics' research in the field of probiotic oral care has led to a pipeline of products ranging from novel anti-infectives to this IVIAT platform technology. Together with our already marketed ProBiora3 and Evora branded probiotics for oral health, we are continuing to build a world-class oral health company," stated Dr. John N. Bonfiglio, President and CEO.


Oragenics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity